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1. Abstract
Background: Rhabdomyosarcoma is a solid tumor, resulting from dysregulation of the skeletal myogenesis
program. For rhabdomyosarcomas (RMS) with a predilection for the head and neck, genitourinary tract, extremities,
trunk, retroperitoneum, the larynx is still an unusual site. Till now only several cases of this laryngeal tumor have
been described in world literature in the adult population. The entire spectrum of genetic factors underlying RMS
development and progression is unclear until today. Multiple signaling pathways seem to be involved in ERMS
development and progression.
Case presentation: In this paper we report an interesting RMS case in which the disease was located within the
glottic region. We report an embryonal rhabdomyosarcoma of the larynx in 33 year-old man. After unsuccessful
chemotherapy hemilaryngectomy was performed. In follow up CT no signs of recurrence were found. Recently
patient is recurrence free for 62 months.
Conclusions: Considering the histological diagnosis and the highly aggressive nature of the lesion for optimal
diagnosis positron electron tomography (PET) and computerized tomography (CT) of the neck and thorax should
be performed. At this time surgical treatment with adjuvant radiotherapy seems to be the treatment of choice for
this disease. Rhabdomyosarcoma of the larynx has a better prognosis than elsewhere in the body, probably
because of its earlier recognition and accessibility to radical surgery.
2. Background
More than 95% of laryngeal tumors in adults are squa-
mous cell carcinoma. Laryngeal rhabdomyosarcomas are
very rare, but extremely malignant tumors. Rhabdomyo-
sarcoma must certainly rank close to, if not the least
common of the laryngeal sarcomas. Most of reported
cases have occurred in children [1]. Rhabdomyosarcoma
arises from undifferentiated mesodermal tissue. It
accounts for 40% of sarcomas found in the head and
neck region. Among sarcomas arising in the larynx,
rhabdomyosarcoma is one of the rarest. The first case of
rhabdomyosarcoma of the larynx was reported by Glick
in 1944 [2]. On gross pathology, rhabdomyosarcomas
are soft, reddish-brown and lobulated. There are four
principal histological varieties of rhabdomyosarcoma:
embryonal, alveolar, pleomorphic and botryoid accord-
ing to their degree of cellular differentiation and matur-
ity. Adult rhabdomyosarcomas are usually composed of
closely packed round cells with peripherally located
nuclei. The cells have glycogen-rich, eosinophilic, vacuo-
lated cytoplasm with cross-striations. Nevertheless they
may have present cytological variability and resemble
different stages of skeletal muscle morphogenesis.
Immunostaining reveals positive findings for muscle-
specific actin, desmin, and myoglobin and more specifi-
cally myogenin and MyoD1 are also positive [3]. Mitoses
are typically absent [4]. Adult embryonal rhabdomyosar-
c o m ah a sp o s s i b l yu n i q u em o l ecular characteristics,
nevertheless it has not been defined yet [5].
At the same time for oncology and surgery specialists
the precise pre-therapeutical staging of tumors of the
musculoskeletal system provides important prognostic
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agement. During therapy imaging is extremely impor-
tant in the follow-up and in diagnosing a possible
recurrent disease [6]. Recently, PET and PET/CT have
emerged as a functional diagnostic imaging modality for
the management of various tumors in adult population
and in the case of RMS FDG PET/CT is more accurate
than CT regarding clinical staging and re-staging of
patients with rhabdomyosarcomas. The overall TNM
staging and M staging accuracies of FDG PET/CT was
defined as high as 86% [7]. The specificity of PET/CT
for the characterization of pulmonary metastases with a
diameter > 0.5 cm and lymph node metastases with a
diameter of <1 cm was significantly increased over that
of CT alone [8].
Till now only several cases of this laryngeal tumor
have been described in world literature in the adult
population [9-11]. Although rhabdomyosarcoma of the
larynx tends to be less aggressive than rhabdomyosar-
coma elsewhere in the head and neck region [12], adult
patients with laryngeal rhabdomyosarcoma often present
at a later stage than other laryngeal tumors, mainly
squamous cell carcinoma [9], which negatively influence
the prognosis. One needs to remember that although
laryngeal involvement by primary and metastatic rhab-
domyosarcoma is very rare, however when occurs-it can
result in life-threatening upper airway obstruction [13].
Rhabdomyosarcoma is a solid tumor, resulting from
dysregulation of the skeletal myogenesis program. Four
histological subtypes occuri nR M S - e m b r y o n a l( E R M S ) ,
alveolar (ARMS), pleomorphic and botryoid. The entire
spectrum of genetic factors underlying RMS develop-
ment and progression is unclear until today. While
chromosomal rearrangements account for the majority
of alveolar tumors, the genetic defects underlying the
pathogenesis of embryonal type remain largely undeter-
mined. Cytogenetically ERMS karyotype is disturbed,
most frequently hyperdiploid, with extra copies of chro-
mosomes 2, 7, 8, 11, 12, 13, and 20. Aneuploidies typical
of sporadic E-RMS include gain of chromosomes 3, 8,
13 and loss of chromosomes 9, 14, X [14]. Although no
consistent structural chromosomal alteration has been
identified in ERMS [15], loss of heterozygosity at
11p15.5 is the most frequent genetic alteration in
embryonal rhabdomyosarcoma [16]. Multiple changes
affecting chromosome arms are being detected in ERMS
cases, including gain or loss of specific regions harbor-
ing cancer progression-associated genes [17]. Aneu-
ploidy and mitotic chromosomal instability observed in
RMS was suggested to be a result of the overexpression
o ft h eA U R K A( a u r o r ak i n a s eA )g e n et h a ti sr e p o r t e d
in all RMS tumors tested [18]. Other gene associated
with RMS development is BUBR1 (budding uninhibited
by benzimidazoles 1 homolog beta)-a key protein in the
mitotic spindle checkpoint and potent inhibitor of
Cdc20. Missense germline mutations of BUB1B were
reported in patients with ERMS and supported the link
between aneuploidy and cancer development [19].
Molecular genetics analyses have not only assisted in
understanding the molecular mechanism in sarcoma
pathogenesis but also demonstrated new relationships
within different types of sarcomas leading to a more
proper classification of sarcomas [20].
Multiple signaling pathways seem to be involved in
ERMS development and progression. Array-based CGH
analysis in primary RMS detected copy number changes
of transcription factors such as MYC-related and the
cytoskeleton and cell adhesion gene-laminin gamma-2
and also p21-activated kinase-1[18]. In the animal
model interaction between HER family genes and the
p53 pathway was shown to be involved in the origin of
human rhabdomyosarcoma [21]. Moreover the patho-
genesis of ERMS was also linked to deregulation of the
hedgehog signaling pathway. Recent findings suggest
that haploinsufficiency for the two tumor suppressor
genes PTCH (patched (Drosophila) homolog (nevoid
basal cell carcinoma syndrome)) and SUFU (suppressor
of fused homolog)-which are both active in this signal-
ing pathway-is frequent in ERMS development [22].
In the majority of ERMS cases screened, overexpres-
sion of MCL1 (induced myeloid leukemia cell differen-
tiation protein) and MAP2K4 (mitogen-activated protein
kinase 4) genes, both involved in cell viability regulation,
was reported [17]. At the same time a few studies per-
formed on series of embryonal tumors suggest that dys-
regulation of RAS function may be relevant to ERMS
disease pathogenesis. NRAS (neuroblastoma RAS viral
(v-ras) oncogene homolog) mutations are found in as
high number as 20% of primary ERMS cases [23].
Another gene of RAS family - HRAS (GTPase HRas
also known as transforming protein p21) - was reported
to be found in the state of uniparental disomy (UPD)
and/or mutated in multiple ERMS cases. It was even
subsequently suggested that HRAS germline mutations
are the first step in ERMS development and are followed
by lost of the other HRAS allele and expression of
mutant HRAS only [24].
Moreover FGFR1 (fibroblast growth factor receptor 1)
overexpression was detected in all primary RMS tumors
and cell lines tested. A hypomethylation of a CpG island
upstream to FGFR1 exon 1 was identified, which sug-
gests a molecular - epigenetic - mechanism of FGFR1
overexpression [25]. Recent studies have also shown a
significant involvement of insulin-like growth factor
(IGF) signaling components in the pathogenesis of rhab-
domyosarcoma. High levels of insulin-like growth factor
II mRNA (IGF-II) were detected in ERMS and increased
transcriptional activity was confirmed to be result of
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pression. Moreover differential expression of IGF path-
way genes can distinguish RMS subtypes, with IGF2
significantly more expressed in ERMS. In such cases it
is possible that PAX3/FKHR fusion gene inhibits IGF2
expression [26]. Embryonal rhabdomyosarcoma is also
characterized by high expression levels of PAX3 and
P A X 7 .A sP A X 3a n dP A X 7a r ek n o w nt op l a yar o l ei n
the regulation of migratory events in embryogenesis, it
is possible that the metastatic potential of ERMS is dri-
ven by PAX overexpression [27]. Moreover ERMS may
overexpress CXCR4 and CXCR7 receptors that bind
prometastatic alpha-chemokine stromal-derived factor-1
(SDF-1).
Not only proteins but also microRNAs (miRNA) have
been implicated in RMS development and the clinical
behavior of RMS. Muscle-specific miRNAs levels are
lower in RMS compared with skeletal muscle but gener-
ally higher than in other normal tissues. Low miR-206
expression correlates with poor overall survival and is
an independent predictor of shorter survival in meta-
static embryonal RMS cases without PAX3/7-FOXO1
fusion genes. Low miR-206 expression also significantly
correlates with high SIOP stage and the presence of
metastases at diagnosis. High miR-206 expression
strongly correlated with expression of genes involved in
muscle differentiation and low expression is associated
with genes linked to MAPkinase and NFKappaB path-
way activation [28]. At the same time miR-183 is signifi-
cantly overexpressed in RMS and is an important
contributor to cell migration and has a potential onco-
genic role through the regulation of 2 tumor suppressor
genes, EGR1 and PTEN [29]. Moreover introduction of
miR-1 and miR-133a into an embryonal rhabdomyosar-
coma-derived cell line is cytostatic, thereby suggesting a
tumor suppressor-like role for these myogenic miRNAs
[30].
All data collected till now suggest the involvement of
genes encoding cell adhesion, cytoskeletal signaling as
well as transcriptional and cell cycle components in
RMS tumorigenesis [18]. It is not possible to indicate
specific steps in cell transformation and further research
is needed to understand the molecular mechanism
underlying RMS carcinogenesis, deregulation of prolif-
eration and differentiation of skeletal myoblasts. We
urge reporting of these rare tumors to enhance under-
standing the genetic component associated with this dis-
ease. Understanding of the molecular biology of
sarcomas is leading towards development of newer and
more effective treatment regimens [20].
3. Case presentation
33 years old male patient was referred to Department of
Otolaryngology, Medical University of Warsaw, due to
isolated longstanding hoarseness. At first visit weight
was 98.5 kg, and height: 186 cm. The patient had no
medical history (diagnoses or operations), was non-smo-
ker and was not under any treatment.
In May 2005, the patient underwent a direct laryngo-
scopy. During the procedure, samples of the tumor
located in right side of glottis were collected for patho-
logic examination. Due to indistinct result of the first
histo-pathological examination, the direct laryngoscopy
was repeated in June 2005 at the Department of Otolar-
yngology of the Medical University of Warsaw, where
the tumor was subsequently resected and examined by a
pathologist. A second histopathological examination
revealed fragments of edematous mucous membrane
partially covered with columnar epithelium, nondysplas-
tic and paraepidermal in majority. In the stroma, active
granulation was identified. Moreover numerous “bizarre”
pleomorphic stromal cells and proliferating epithelial
cells were identified. Due to the lack of correlation
between the result of the pathological examination and
the clinical manifestation, the slides were sent to The
Maria Sklodowska-Curie Memorial Cancer Centre and
the Institute of Oncology in Warsaw for revision and
additional specification. This consultation revealed rhab-
domyosarcoma embryonale. For treatment planning in
August 2005, computed tomography (CT) examination
of the larynx was performed with contiguous 2.7 mm
t h i c ks l i c e sa n ds h o w e dap o o r l yd e l i n e a t e dt u m o r
l o c a t e do nt h er i g h ts i d eo ft h el a r y n x ,i n v a d i n gt h e
vocal fold and the ventricular fold, contracting the pyri-
form recess and constricting the glottis. Contrast
enhancement in the tumor was observed in the CT
scans (Figure 1).
Figure 1 A two-phase CT scan, performed in August 2005
showing a 24.8 × 15.7 mm poorly delineated tumor, located at
the right side of the larynx, invading the vocal fold and the
ventricular fold, contracting the pyriform recess and
constricting the glottis.
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localization two cycles of VAC1 induction chemotherapy
were administered (VAC1-vincristine, D-aktynomycine
and cyclophosphamide: 1.5 MG/M2 IV day 1, 0.3 MG/
M2 IV days 1-5, 150 MG/M2 IV days 1-5; every 28
days). The first chemotherapy cycle began on September
8
th 2005. It was followed by chemo-radiotherapy in
November and December 2005. Radiotherapy was admi-
nistered in fractions of 200 cGy and total dose of 7000
cGy over 6 weeks. In parallel two cycles of maintenance
VAC1 chemotherapy were given. CT was performed on
the February 1
st 2006 and revealed no tumor regression
according to RECIST criteria. In accordance to CT scan
no significant clinical response was observed. Subse-
quently on February 3
rd 2006 vertical hemilaryngectomy
was performed. Postoperative histopathological examina-
tion confirmed rhabdomyosarcoma located in the right
side of the larynx. All examined margins were negative
for cancer cells. The patient was discharged from the
hospital with tracheostomy and nasogastric tube.
First cycle of adjuvant chemotherapy was administered
on April 21
st 2006. Chemotherapy was continued until
August 24
th 2006. In total the patient received twelve
cycles of VAC1, with 50% dose reduction after V cycle
due to neutropenic fever in November 2005. The patient
had the nasogastric tube removed in May 2006 and was
decaniulated in October 2006. Following the surgery,
the patient was monitored by a laryngologist and oncol-
ogist and underwent regular fiberoptic examinations of
the larynx and direct laryngoscopy in case of unclear
fiberoptic examination results. Follow-up CTs were per-
formed in October 2006, June 2007, November 2007,
June 2008 and March 2009, and did not reveal any
tumor recurrence (Figure 2). Due to persistent swelling
in the region of the arytenoid cartilage, a PET examina-
tion was performed on February 1
st 2007. This examina-
tion did not reveal any focal lesions suggesting
metastases. On March 2007, a check-up direct laryngo-
scopy with deep tissue biopsy was performed. The histo-
pathological examination was negative. The patient
remains under strict laryngological and oncological
monitoring and no symptoms or signs of disease recur-
rence have been noticed. On June 24
th 2010 patient had
a follow-up PET-CT scan, which revealed normal glu-
cose metabolism in the postoperative site (Figure 3). No
metastases or local recurrence were found until now
(May 2011).
4. Conclusions
Diagnosis of rhabdomyosarcoma may be difficult. Most
of all adequate biopsy material is crucial in the identi-
fication of this tumor. The delay in diagnosis may arise
as a consequence of diagnosis of inflammatory or
benign laryngeal disease. The timely diagnosis of a
laryngeal neoplasm depends on maintaining a high
index of suspicion in a patient with progressive airway
obstruction, dysphagia or dysphonia, and conducting
an efficient work-up-including magnetic resonance
imaging and direct laryngoscopy under general
anesthesia in association with bronchoscopy-in order
to define the extent of the lesion, rule out multiple
lesions, establish and maintain an airway, and perform
a biopsy of the tumor [31]. Emrbyonal rhabdomyosar-
coma of the larynx must be differentiated from other
common histologic types of larynx tumors in that it
differs significantly with respect to its management.
Figure 2 A two-phase CT scan, performed in March 2009
showing the postoperative thyroid cartilage defect on the
right side. Soft tissue mass protruding into the supraglottic region
on the left side in the aryepiglottic fold is identical to changes
described in 2007 and 2008 (no signs of recurrence).
Figure 3 A PET/CT performed in June 2010 showing no local
recurrence in the larynx.
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no treatment guidelines have been established. Only
several of these tumors have been adequately described
in world literature in the adult population. Adult
patients with laryngeal rhabdomyosarcoma may pre-
sent at a later stage than other laryngeal tumors,
including squamous cell carcinoma. Treatment of
rhabdomyosarcoma should be a multimodality effort.
Although laryngeal RMS is an extremely rare tumor
which responds to surgery, but also may be treated by
means of chemo-radiotherapy. Further studies are
needed in order to improve our understanding of its
biological behavior and to define the most appropriate
therapeutic approach. Considering the histological
diagnosis and the highly aggressive nature of the lesion
for optimal diagnosis positron electron tomography
(PET) and computerized tomography (CT) of the neck
and thorax should be performed.
At this time surgical treatment with adjuvant radio-
therapy seems to be the treatment of choice for this dis-
ease. If possible initial efforts should be aimed at tumor
size reduction, as unlike other regions of the body the
head and neck region is limited by anatomic constraints
and therefore, surgical treatment in this area is limited
accordingly. Until recently, rhabdomyosarcomas carried
a dismal prognosis; however, combined treatment with
surgery, irradiation, and triple chemotherapy appears to
have improved the outlook. This should probably be the
treatment for laryngeal rhabdomyosarcomas. It would
seem that a rhabdomyosarcoma of the larynx has a bet-
ter prognosis than elsewhere in the body, probably
because of its earlier recognition and accessibility to
radical surgery.
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